Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Common Equity (2016 - 2025)

Historic Common Equity for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to $3.2 million.

  • Palisade Bio's Common Equity fell 5139.23% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 5139.23%. This contributed to the annual value of $7.5 million for FY2024, which is 3377.53% down from last year.
  • Palisade Bio's Common Equity amounted to $3.2 million in Q3 2025, which was down 5139.23% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Palisade Bio's Common Equity peaked at $15.8 million during Q2 2023, and registered a low of -$20.1 million during Q1 2021.
  • In the last 5 years, Palisade Bio's Common Equity had a median value of $7.0 million in 2024 and averaged $6.0 million.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 30107.32% in 2021, then surged by 27520.78% in 2023.
  • Palisade Bio's Common Equity (Quarter) stood at $3.9 million in 2021, then skyrocketed by 218.34% to $12.5 million in 2022, then decreased by 9.34% to $11.3 million in 2023, then tumbled by 33.78% to $7.5 million in 2024, then crashed by 57.13% to $3.2 million in 2025.
  • Its Common Equity was $3.2 million in Q3 2025, compared to $2.6 million in Q2 2025 and $5.3 million in Q1 2025.